Neogen Corporation

Neogen Corporation

NEOGNYSE / NASDAQHealthcareMid cap

$10.55-$0.30 (-2.8%)

Last close · Data as of Nov 20, 2026

Market cap
$2.0B
P/E
-1.8x
EV / EBITDA
-2.9x
Revenue
$894.7M
Net margin
-122.1%
ROCE
-0.1%

+95.0% over the last year

Neogen Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-10.0%
3M
-10.8%
6M
+19.5%
1Y
+95.0%
5Y
-76.0%

52-week range

Day change -$0.30 (-2.8%) from $10.85 to $10.55 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in NEOG, bought on each weekday since 2021.

News & filings

What Neogen filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 1.1 billion US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 3.32 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety.

Read moreShow less

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Sector
Healthcare
Shares outstanding
217.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.0B
P/E
-1.8x
P/B
1.0x
EV / EBITDA
-2.9x
EV / Sales
3.1x
P/S
2.2x
52-week high
$13.98
52-week low
$5.41

Profitability

Operating margin
-0.2%
Net margin
-122.1%
EBITDA margin
-104.6%
ROE
-52.7%
ROCE
-0.1%
ROA
-31.7%
Asset turnover
0.26

Growth

Revenue
$894.7M
Revenue growth, 1Y
-3.2%
Revenue CAGR, 3Y
19.3%
Net profit growth, 1Y
11491.6%
Free cash flow
-$46.4M

Solvency

Current ratio
3.32
Debt / Equity
0.43
Debt / Assets
0.26
CFO / Net profit
-0.05
Cash / Market cap
6.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$894.7M
Cost of revenue$473.3M
Gross profit$421.4M
Operating expenses$423.1M
Research and development$21.1M
Selling, general and administrative$402.0M
Operating income-$1.7M
Interest and other-$1.1B
Pretax income-$1.1B
Tax and other-$41.1M
Net income-$1.1B

Revenue and net profit

Revenue fell 3.2% in FY2025; net profit is the dashed line.

Neogen Corporation revenue and net profit by fiscal year
Neogen Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$527.2M$48.3M
FY2023$822.4M-$22.9M
FY2024$924.2M-$9.4M
FY2025$894.7M-$1.1B

Cash flows

FY2025: $58.2M from operations, -$46.4M free after investment (dashed).

Neogen Corporation operating and free cash flow by fiscal year
Neogen Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$68.0M$43.6M
FY2023$41.0M-$24.7M
FY2024$35.3M-$76.2M
FY2025$58.2M-$46.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$894.7M-3.2%1Y
EBITDA
-$935.8M-619.0%1Y
Net profit
-$1.1B
Cash from operations
$58.2M+65.2%1Y
Free cash flow
-$46.4M
Revenue CAGR, 3Y
19.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$894.7M-$935.8M-$1.1B-$46.4M-52.7%-3.2%+11491.6%

Monthly returns

Month-by-month returns of NEOG across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.4B
Liabilities$1.4B
Equity$2.1B
Paid-in capital$2.6B
Retained earnings-$536.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NEOG highlighted.

P/E against peers

NEOG has no positive P/E; the peer median is 11.9x.

Not shown (no positive earnings and no EV / Sales): Neogen Corporation, Supernus Pharmaceuticals, Inc., Acadia Healthcare Company, Inc., Sarepta Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Neogen CorporationNEOGthis company$2.0B-1.8x1.0x-52.7%-2.9x
Supernus Pharmaceuticals, Inc.SUPN$2.6B-67.3x2.4x-3.6%58.9x
TransMedics Group, Inc.TMDX$2.5B13.0x5.2x40.2%16.8x
Acadia Healthcare Company, Inc.ACHC$2.3B-2.1x1.2x-56.6%-6.5x
Prestige Consumer Healthcare Inc.PBH$2.2B11.3x1.1x10.1%9.5x
LeMaitre Vascular, Inc.LMAT$2.1B37.0x5.4x14.7%25.3x
Select Medical Holdings CorporationSEM$2.0B14.0x1.2x8.6%9.2x
ADMA Biologics, Inc.ADMA$1.8B12.6x3.9x30.8%9.3x
Sarepta Therapeutics, Inc.SRPT$1.8B-2.5x1.5x-62.5%-3.2x
Peer median—11.9x2.0x9.3%9.4x

Year-to-date ROI

NEOG since 1 January, against earlier years.

Historical volatility

NEOG's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Neogen Corporation operating margin by fiscal year
Neogen Corporation operating margin by fiscal year
DateOperating margin
FY202211.1%
FY20234.6%
FY20246.3%
FY2025-0.2%
LineFY2025
Cost of revenueCost Of Revenue$473.3M
Gross profitGross Profit$421.4M
Operating expensesOperating Expense$423.1M
Research and developmentResearch And Development$21.1M
Total expensesTotal Expenses$896.3M
Pretax incomePretax Income-$1.1B

Learn while you research

Academy chapters picked for Neogen Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →